Oncology Biosimilars Market Outline


Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. Oncology biosimilars are similar to oncology biological molecules are approved for the treatment of different types of cancers. Oncology biosimilars are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.


Market Dynamics: Oncology Biosimilars Market

Increase in the prevalence of certain types of cancers around the world, rise in R&D activities for the innovation of biosimilars, growing funding from public and private sector, and patent expiration of blockbuster drugs are anticipated to fuel the oncology biosimilars market over the forecast period. Moreover, cost-effective biosimilar products, strong biosimilar product pipeline, and government initiations for the prevention of cancer are bolster the oncology biosimilars market. However, stringent regulatory policies, high cost for R&D, complexity in the development of biosimilars, and alternative therapies for the cancer treatment might restrain the growth of oncology biosimilars market.


Market Scope: Oncology Biosimilars Market

Based on the drug class, the market is segmented into the following:

  • G-CSF Drugs
  • Monoclonal Antibodies
  • Hematopoietic Drugs
  • Others


Based on the route of administration, the market is segmented into the following:

  • Oral
  • Parenteral


Based on the disease type, the market is segmented into the following:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Leukemia
  • Neutropenia
  • Blood Cancer
  • Others


Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies


Based on the region, the market is segmented into the following:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa


Market Summary: Oncology Biosimilars Market

Increase in the prevalence of cancer expected to drive the oncology biosimilars market over forecast period. According to World Cancer Research Fund International 2012, approximately 14.1 Mn cancer cases observed around the world and it is expected to increase to 24 Mn by 2035. Moreover, increase in demand for affordable cancer therapies, rise in focus on R&D activities by the market players to develop generic drugs and biosimilars to combat the cancer at all stages are anticipated to fuel the market growth. In addition, acquisitions and collaborations are the strategies adopted the market players to stay releven to the industry. For instance, in September 2017, Fresenius Kabi acquired Merck KGaA’s biosimilars business including oncology and autoimmune disease product pipeline. Furthermore, product approval and product launchings by market players also expected to boost the oncology biosimilars market. For instance, in September 2017, Amgen received FDA approval for its oncology biosimilar product Mvasi (bevacizumab-awwb) for treating the multiple types of cancers.


Regional Analysis:  Oncology Biosimilars Market

Geographically, global market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America oncology biosimilars market is growing due to increase in R&D for the innovation of newer oncology biosimilar drugs, product approvals from FDA, and acquisitions and collaborations between the market players. Europe market has a significant share owing to collaboration between the market players, and increase in the prevalence of cancer. Asia Pacific market is projected to grow at notable rate due to rise in prevalence of various types of cancers, increase in R&D activities for the development of newer biosimilar products, and rise in medical tourism in Asia Pacific countries. Latin America oncology biosimilars market has a notable share owing to expansion of business by market players, development in economic growth, and rise in awareness about oncology biosimilars among the physicians are fuel the market.


Competition Assessment: Oncology Biosimilars Market

  • Reddy’s Laboratories Ltd. (India)
  • Pfizer Inc. (U.S.)
  • Celltrion Inc. (South Korea)
  • GlaxoSmithKline plc (U.K.)
  • Allergan Plc. (U.K.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sandoz International GmbH (Novartis AG) (Switzerland)
  • Simcere Pharmaceutical Group (China)
  • Amgen Inc. (U.S.)
  • Fresenius Kabi AG (Fresenius SE & Co. KGaA) (Germany)
  • Biocon (India)


Notable Market Developments: Oncology Biosimilars Market

  • In September 2017, Amgen, Inc. and Simcere pharmaceutical Group inked an agreement to co-develop and commercialization of four undisclosed biosimilars in China used in the treatment of oncology and inflammation


Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2019) and forecast (2020 to 2026)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market



PBI Location Map


Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX